Literature DB >> 10203034

Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macaques infected with SIV.

D T Evans1, L A Knapp, P Jing, J L Mitchen, M Dykhuizen, D C Montefiori, C D Pauza, D I Watkins.   

Abstract

Highly polymorphic HLA class I molecules may influence rates of disease progression of HIV-infected individuals. Recent evidence suggests that individuals who mount vigorous CTL responses to multiple HIV-1 epitopes have reduced viral loads, and survive longer than individuals that make a less robust or less diverse CTL response. It has been difficult, however, to define associations between particular HLA class I alleles and rates of disease progression. This may be due, in part, to the uncontrolled variables associated with naturally acquired HIV infections. Studies using MHC-defined, non-human primates infected with well characterized viral stocks should help to clarify this relationship. To explore the possibility that MHC class I polymorphism can influence disease progression, we infected four Mamu-DRB-identical individuals from a family of MHC-defined rhesus macaques intravenously with 40 TCID50SIVmac239. Two of these macaques developed severe wasting and were euthanized within 80 days of infection, while the other two survived for more than 400 days without showing any symptoms of disease. Since all four of these macaques were Mamu-DRB-identical, we were able to exclude the MHC class II DRB loci as determinant of disease progression. Interestingly, both of the slow progressors made CTL responses to the same three SIV CTL epitopes, which were restricted by two molecules (Mamu-B*03 and B*04) encoded by their common maternal haplotype. The two rapid progressors did not share this haplotype with the slow progressors, and we were unable to detect CTL responses in these two siblings. These observations implicate products of the Mamu-B*03 and B*04 alleles in resistance to disease progression in this family of SIV-infected macaques, and provide additional evidence that certain MHC class I-restricted CTL responses may play a significant role in delaying the onset of AIDS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10203034     DOI: 10.1016/s0165-2478(98)00151-5

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  35 in total

1.  CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins.

Authors:  Chungwon Chung; Robert H Mealey; Travis C McGuire
Journal:  Virology       Date:  2004-09-15       Impact factor: 3.616

2.  Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope.

Authors:  Fred W Peyerl; Heidi S Bazick; Michael H Newberg; Dan H Barouch; Joseph Sodroski; Norman L Letvin
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.

Authors:  Koen K A Van Rompay; Raman P Singh; Walid Heneine; Jeffrey A Johnson; David C Montefiori; Norbert Bischofberger; Marta L Marthas
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Simian immunodeficiency virus SIVmac239 infection of major histocompatibility complex-identical cynomolgus macaques from Mauritius.

Authors:  Roger W Wiseman; Jason A Wojcechowskyj; Justin M Greene; Alex J Blasky; Tobias Gopon; Taeko Soma; Thomas C Friedrich; Shelby L O'Connor; David H O'Connor
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

5.  Infectious molecular clones from a simian immunodeficiency virus-infected rapid-progressor (RP) macaque: evidence of differential selection of RP-specific envelope mutations in vitro and in vivo.

Authors:  Takeo Kuwata; Houman Dehghani; Charles R Brown; Ronald Plishka; Alicia Buckler-White; Tatsuhiko Igarashi; Joseph Mattapallil; Mario Roederer; Vanessa M Hirsch
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

6.  Unique pathology in simian immunodeficiency virus-infected rapid progressor macaques is consistent with a pathogenesis distinct from that of classical AIDS.

Authors:  Charles R Brown; Meggan Czapiga; Juraj Kabat; Que Dang; Ilnour Ourmanov; Yoshiaki Nishimura; Malcolm A Martin; Vanessa M Hirsch
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

7.  CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.

Authors:  Koen K A Van Rompay; Raman P Singh; Bapi Pahar; Donald L Sodora; Casey Wingfield; Jonathan R Lawson; Marta L Marthas; Norbert Bischofberger
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Treatment with anti-FasL antibody preserves memory lymphocytes and virus-specific cellular immunity in macaques challenged with simian immunodeficiency virus.

Authors:  Bhawna Poonia; Maria S Salvato; Hideo Yagita; Toshihiro Maeda; Ko Okumura; C David Pauza
Journal:  Blood       Date:  2009-06-04       Impact factor: 22.113

9.  Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques.

Authors:  Vanessa M Hirsch; Sampa Santra; Simoy Goldstein; Ronald Plishka; Alicia Buckler-White; Aruna Seth; Ilnour Ourmanov; Charles R Brown; Ronald Engle; David Montefiori; Jennifer Glowczwskie; Kevin Kunstman; Steven Wolinsky; Norman L Letvin
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.

Authors:  Kara Jensen; Myra Grace Dela Pena-Ponce; Michael Piatak; Rebecca Shoemaker; Kelli Oswald; William R Jacobs; Glenn Fennelly; Carissa Lucero; Katie R Mollan; Michael G Hudgens; Angela Amedee; Pamela A Kozlowski; Jacob D Estes; Jeffrey D Lifson; Koen K A Van Rompay; Michelle Larsen; Kristina De Paris
Journal:  Clin Vaccine Immunol       Date:  2017-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.